Table 3.
Cox regression analysis for overall survival
| Variable | Univariate model | Multivariate modela | ||
|---|---|---|---|---|
|
Hazard ratio (95% CI) |
p |
Hazard ratio (95% CI) |
p | |
| T | 1.34 (0.65–2.86) | 0.39 | 1.05 (0.44–2.51) | 0.92 |
| N | 2.62 (1–6.87) | 0.04a | 2.59 (0.95–7.02) | 0.06 |
| Cisplatin | 0.55 (0.18–1.69) | 0.3 | 0.48 (0.13–1.78) | 0.27 |
| VCT | 1.01 (1–1.02) | 0.01a | ||
| VCT1 14 Gy | 1.02 (0.99–1.06) | 0.11 | ||
| VCT2 28 Gy | 1.04 (1–1.08) | 0.01a | ||
| VCT3 36 Gy | 1.03 (0.99–1.08) | 0.05 | ||
| V[18F]LT | 1.03 (0.99–1.07) | 0.06 | ||
| V[18F]LT1 14 Gy | 1.02 (0.98–1.07) | 0.26 | ||
| V[18F]LT2 28 Gy | 1.14 (1.02–1.28) | 0.02a | ||
| V[18F]DG | 1.01 (0.99–1.04) | 0.07 | ||
| [18F]DG SUVmax | 1.08 (0.94–1.24) | 0.26 | ||
| TMR max | 6.36 (1.67–24.17) | 0.006a | 4.95 (1.09–22.51) | 0.04a |
| TMR max 36 Gy | 2.87 (0.58–14.14) | 0.19 | ||
| [18F]DG MTV | 1.01 (0.99–1.03) | 0.06 | ||
| [18F]LT MTV | 1.02 (1–1.04) | 0.02a | ||
| [18F]MISO MTV | 1.06 (0.92–1.22) | 0.38 |
CI, confidence interval; [18F]-FDG, [18F]-2-flu-2-deoxy-D-glucose; [18F]-FLT, [18F]-flu-3'deoxythymidine; [18F]-FMISO, [18F]-flumisonidazole; MTV, metabolic tumour volume; SUVmax, maximum standardised uptake value; TMR, tumour-to-muscle ratio;VCT, CT tumour volume.
Only TMR max remained significant when adjusted for known clinical factors (Tumour and nodal status and concomitant using cisplatin) in a multivariate model.
V—baseline tumour volume in CT, FDG, FLT, FMISO.
V14Gy, 28 Gy, 36 Gy—tumour volume measured at indicated time point during treatment.
VFMISO 1.5, 1.6—hypoxic tumour volume based on indicated threshold levels.
MTV FDG, FLT, FMISO—MTV.
SUVmax—baseline maximum standardised uptake value.
TMRmax—baseline TMR based on SUVmax.
TMRmax 36 Gy—TMR based on SUVmax at 36 Gy.
Multivariate analysis results for the only model in which baseline TMRmax was significant.